AIDS China Voice | Dr. Biao Zhu: Changing Disease Spectrum of Hospitalized HIV-Infected Patients in Eastern China

AIDS China Voice | Dr. Biao Zhu: Changing Disease Spectrum of Hospitalized HIV-Infected Patients in Eastern China

From July 22-26, 2024, the 25th International AIDS Conference（AIDS 2024） was held in Munich, Germany, bringing together 15,000 professionals and advocates from around the world to discuss the latest advancements and future challenges in HIV prevention and treatment. At the conference, Dr. Biao Zhu from the First Affiliated Hospital,Zhejiang University School of Medicine presented a retrospective study conducted by his team. The report analyzed the changing disease spectrum of hospitalized HIV-infected patients in comprehensive hospitals in Eastern China over the past 12 years, revealing not only the survival status of HIV-infected patients in the Yangtze River Delta region but also significant changes in their disease spectrum as they achieve long-term survival.
Dr. Qian Jiang Elaborates on Standard Treatment Models and Unmet Needs in Newly Diagnosed Chronic Myeloid Leukemia | The 8th CSCO Hematology Academic

Dr. Qian Jiang Elaborates on Standard Treatment Models and Unmet Needs in Newly Diagnosed Chronic Myeloid Leukemia | The 8th CSCO Hematology Academic

To further enhance the diagnostic and treatment techniques for leukemia and lymphoma in China, the 8th Hematology Oncology Academic Conference was held from July 26 to 28 in Harbin. This event was jointly organized by the Chinese Society of Clinical Oncology (CSCO), the CSCO Leukemia Expert Committee, and the Lymphoma Expert Committee, and co-hosted by the Harbin Institute of Hematology and Oncology and Peking University Cancer Hospital. The conference aimed to provide a significant platform for in-depth learning and extensive exchange among experts and scholars in the field of hematologic oncology. On this occasion, Hematology Frontier had the privilege of inviting Dr. Qian Jiang from Peking University People's Hospital to share her insights on the treatment models and unmet needs for newly diagnosed chronic myeloid leukemia (CML) patients.
Diabetes Increases the Risk of Death or Liver Transplantation in Patients with Alcoholic Cirrhosis

Diabetes Increases the Risk of Death or Liver Transplantation in Patients with Alcoholic Cirrhosis

Over time, alcohol consumption has become a significant public health concern. Alcohol is associated with more than 200 diseases, including diabetes and cirrhosis, contributing to 5.3% of global mortality. Despite increased awareness of alcohol's harmful effects, overall consumption levels have not decreased. Previous studies have investigated the impact of diabetes on patients with alcoholic cirrhosis, but the relationship between diabetes and clinical outcomes in these patients has remained unclear. Recently, a study published in Hepatology International has shed light on the relationship between diabetes and clinical outcomes in patients with alcohol-related cirrhosis.
CDM Monthly Review · Issue 83

CDM Monthly Review · Issue 83

Greetings to all experts and colleagues. In this issue of CDM Monthly Review (Issue 83), we will share five recent papers in the field of diagnosis and treatment of portal hypertension in liver cirrhosis (three on diagnostic monitoring and two on multidisciplinary treatment). The guest experts for this issue's review are Dr. Qianwen Zhao from the Department of Infectious Diseases at Nanjing Drum Tower Hospital, Dr. Yanna Liu from the Liver Disease and Gastroenterology Center at Beijing You'an Hospital , Capital Medical University, Dr. Kefeng Jia from Tianjin Third Central Hospital, and Dr. Wenhui Zhang from the Department of Gastroenterology at Beijing Daxing District People's Hospital.
JOH丨Impact of Pre-Transplant Immunotherapy on Post-Transplant Outcomes in Liver Cancer

JOH丨Impact of Pre-Transplant Immunotherapy on Post-Transplant Outcomes in Liver Cancer

The Journal of Hepatology (JOH) recently published an online systematic review and individual patient data meta-analysis conducted by Cedars-Sinai Medical Center in Los Angeles. The study investigates the impact of using immune checkpoint inhibitors (ICIs) for hepatocellular carcinoma (HCC) before liver transplantation on various key clinical outcomes post-transplantation. The findings reveal that while ICIs treatment may increase the risk of post-transplant rejection, the overall risk remains manageable, with patient age and ICI clearance time being closely related to rejection risk. This study provides valuable clinical data to support the use of ICIs before liver transplantation, offering new insights and directions for research and clinical practice in this area.
Artificial Liver Support System Improves Gut Microbiota and Serum Bile Acids in Patients with Acute-on-Chronic Liver Failure

Artificial Liver Support System Improves Gut Microbiota and Serum Bile Acids in Patients with Acute-on-Chronic Liver Failure

Most patients with acute-on-chronic liver failure (ACLF) exhibit varying degrees of cholestasis. Previous studies have shown that compared to standard medical treatment alone, the artificial liver support system (ALSS) can improve prognosis and extend survival time in ACLF patients. Additionally, research has confirmed gut microbiota dysbiosis in ACLF patients. However, the specific impact of ALSS on the gut microbiota composition in these patients remains unclear. Considering the complex interactions between gut microbiota, bile acids (BAs), and the liver, researchers conducted a study to elucidate the unique effects of ALSS on gut microbiota and serum BAs in ACLF patients. Furthermore, the study visualized the relationships between gut microbiota, serum BAs, and clinical outcomes in ACLF patients using correlation heatmaps, providing insights into potential therapeutic targets for ACLF. The study was recently published in Hepatology International.
Interview with Dr. Bijie Hu, Chairman of the 2024 SIFIC Conference

Interview with Dr. Bijie Hu, Chairman of the 2024 SIFIC Conference

Since its inception in 2005, the Shanghai International Forum for Infection Control (SIFIC) has grown over the past two decades. Known for its professionalism and forward-thinking approach, SIFIC has become a significant academic platform in China for the fields of hospital infection, major infectious diseases, and the prevention and control of multidrug-resistant organisms. Each year's academic conference not only boasts a large scale but also serves as a grand academic gathering for infection control experts and scholars from both domestic and international arenas. In the recently concluded SIFIC 2024 conference, one of the founders and current Chairman of SIFIC, Dr. Bijie Hu from Zhongshan Hospital, Fudan University, shared with Infectious Disease Frontier the development and achievements of SIFIC, as well as his profound insights into the future of infection control in China. Through his perspective, we gain a glimpse into the evolution of the field, the challenges it currently faces, and the direction it is likely to take in the future.
AIDS China Voice | Dr. Jie Peng: Research on HBsAg Clearance in HIV/HBV Co-infected Patients

AIDS China Voice | Dr. Jie Peng: Research on HBsAg Clearance in HIV/HBV Co-infected Patients

The 25th International AIDS Conference (AIDS 2024) was held in Munich, Germany, from July 22 to 26, 2024. This highly anticipated academic event showcased some of the most cutting-edge research in the field. Currently, clinical cures for people co-infected with HIV and HBV are still in the exploratory stage. At the conference, a research study conducted by Dr. Jie Peng’s team from the Nanfang Hospital was selected for poster presentation. The study revealed that after receiving antiretroviral therapy, HIV/HBV co-infected patients had a higher rate of HBsAg clearance. Baseline HBsAg levels and CD4 cell counts were identified as predictive factors for HBsAg clearance in these patients. We have invited Dr. Jie Peng to provide an insightful interpretation of these research findings for our readers.
ISTH Guideline丨Latest ISTH Clinical Practice Guidelines for the Treatment of Hemophilia A and B Published

ISTH Guideline丨Latest ISTH Clinical Practice Guidelines for the Treatment of Hemophilia A and B Published

Hemophilia, a rare congenital bleeding disorder, is caused by pathogenic variants in the encoding genes, leading to the complete or partial deficiency of clotting factors VIII (Hemophilia A) or IX (Hemophilia B). Treating hemophilia involves certain complexities, and until now, no evidence-based clinical practice guidelines based on the GRADE methodology have been established to guide treatment. The International Society on Thrombosis and Haemostasis (ISTH) has developed evidence-based clinical practice guidelines aimed at systematically reviewing the relevant evidence to provide a scientific basis for treatment decisions in Hemophilia A and B, thereby supporting healthcare providers in their clinical practice. To this end, ISTH formed a globally representative, multidisciplinary guideline panel that prioritized clinical questions based on their urgency and the importance of outcomes to patients and clinicians.
Exploring the Frontier and Building the Future: Dr. Tiejun Gong Discusses Standards and Innovations in Hematologic Oncology Treatment

Exploring the Frontier and Building the Future: Dr. Tiejun Gong Discusses Standards and Innovations in Hematologic Oncology Treatment

The warm summer in Harbin was matched by a surge of medical wisdom. The 8th Hematology  Academic Conference of the Chinese Society of Clinical Oncology (CSCO), hosted by the Harbin Institute of Hematology and Oncology and Peking University Cancer Hospital, was held from July 26 to 28, 2024, in Harbin. This grand event brought together many top experts and scholars from both domestic and international fields, showcasing the latest research results and clinical experiences in the treatment of hematologic malignancies. Hematology Frontier had the privilege of inviting Dr. Tiejun Gong from the Harbin Institute of Hematology and Oncology to share his unique insights and experiences from this conference, highlight the key expert guidelines, and discuss the standout content of the Northeast Hematologic Oncology Standardized Diagnosis and Treatment session.